

POSITIVE RESULTS FROM 28-DAY TOXICOLOGY STUDY ON FLAVOCIDE™

- **Positive results have been received from the 28-day repeat dose oral and dermal mammalian toxicity studies with Flavocide™**
- **Results showed no observable adverse effects on rats from exposure to Flavocide at the doses tested**
- **The results provide further supporting data towards creation of a global registration-enabling data package to support the commercialisation of Flavocide**

Bio-Gene Technology Limited (“Bio-Gene”) is pleased to report positive results from the 28-day oral and dermal toxicology studies in rats as part of the mammalian toxicity testing program with technical grade flavesone, the active constituent contained in Flavocide.

The results of these studies showed no observable adverse effects on rats from exposure to Flavocide at the doses tested. These results will assist in determining appropriate doses for the next stage of studies which will include longer term repeat dose toxicity testing. The longer term repeat dose toxicity tests are a standard requirement for registration of insecticide products worldwide.

Peter May, Executive Director R&D for Bio-Gene said: “These results represent an important de-risking milestone for ongoing commercial development, and are particularly valuable to prospective commercial partners. In addition, they will form the basis for determining the parameters of longer-term repeat dose toxicity testing, which is an essential and important component of Flavocide’s data package in support of global registration and commercialisation of the product.”

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger
Chief Executive Officer
P: 03 9628 4178
E: bgt.info@bio-gene.com.au

Roger McPherson
CFO & Company Secretary
P: 03 9628 4178
E: bgt.info@bio-gene.com.au

Media/investor relations:

Ben Walsh or Kyahn Williamson
WE Buchan
T: 03 9866 4722
E: bio-gene@we-buchan.com

About Bio-Gene Technology Limited

Bio-Gene is an Australian agtech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across animal health and crop protection, as well as in public health, and in consumer applications.

The Company’s aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.

Bio-Gene Technology Limited

ABN: 32 071 735 950

Suite 1, Level 6, 50 Queen St, Melbourne, VIC 3000